Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for improving immunogenicity of 13-valent pneumococcal polysaccharide-protein conjugate

A pneumococcal polysaccharide and immunogenicity technology, applied in the direction of carrier-binding antigen/hapten components, antibacterial drugs, drug combinations, etc., can solve problems such as poor immune effect, large variability of immunogenicity, and differences in immunogens

Active Publication Date: 2014-10-22
KANVAX BIOPHARM
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the immunogenicity of the existing pneumococcal polysaccharide-protein conjugate vaccines on the market is highly variable. This variability is not only due to the structural differences of polysaccharides of different serotypes, but also the use of different immunogenic protein carriers. It is also the main cause of the immunogenic difference of 13-valent pneumococcal polysaccharide protein conjugates
In certain high-risk populations, such as children, the elderly, or those who are immunocompromised, low-immunogenicity polysaccharide-protein conjugate vaccines are less effective and have limited protection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for improving immunogenicity of 13-valent pneumococcal polysaccharide-protein conjugate
  • Method for improving immunogenicity of 13-valent pneumococcal polysaccharide-protein conjugate
  • Method for improving immunogenicity of 13-valent pneumococcal polysaccharide-protein conjugate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The specific implementation method of the present invention is illustrated below, but not limited to the following examples.

[0032] The first step, preparation of carrier protein and pneumococcal polysaccharide

[0033] In order to illustrate the effectiveness of the present invention, two carrier proteins were prepared, namely the protein carrier OVApCRM197A containing OVAp and the protein carrier CRM197A not containing OVAp. Among them, the CRM197A protein carrier is used to synthesize the 13-valent pneumococcal polysaccharide-CRM197A conjugate sample for control.

[0034] 1. Design of amino acid sequence of CRM197A protein carrier and OVApCRM197A protein carrier

[0035] 1. Design of amino acid sequence of CRM197A protein carrier

[0036] Diphtheria toxin is expressed in Bacillus diphtheriae by β-phage with diphtheria toxin gene, and exists in the form of polypeptide in the bacterial cytoplasm, consisting of 560 amino acids with a molecular weight of 62,000 Dalto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for improving immunogenicity of a 13-valent pneumococcal polysaccharide-protein conjugate. The method comprises the following steps of 1, adding ISQAVHAAHAEINEAGR OVAp into CRM197A and producing OVAp-containing CRM197A protein carrier (OVApCRM197A), and 2, connecting 13 different serotypes of polysaccharides to the OVApCRM197A by a covalent bond so that a 13-valent pneumococcal polysaccharide-OVApCRM197A conjugate is obtained. Compared with a 13-valent pneumococcal polysaccharide-CRM197A conjugate prepared from corresponding OVAp-less CRM197A, the 13-valent pneumococcal polysaccharide-OVApCRM197A conjugate improves immunogenicity by 3-5 times.

Description

technical field [0001] The invention relates to a method capable of enhancing the immunogenicity of a 13-valent pneumococcal polysaccharide protein conjugate. Background technique [0002] When the polysaccharide is covalently linked to the protein carrier, the polysaccharide of the hapten can be converted into a whole antigen, so that the immunogenicity of the polysaccharide is enhanced. The polysaccharide-protein conjugated vaccine synthesized by this method has been widely used in children, successfully preventing bacterial infections including pneumococcus, meningococcus and Haemophilus influenzae type b. [0003] There are a variety of protein carriers used to synthesize polysaccharide-protein conjugates, such as tetanus toxoid, diphtheria toxoid, diphtheria toxin variant CRM197, and Haemophilus epidemic surface protein D produced by genetic recombination technology; however, due to different protein The immunogenicity of polysaccharide-protein conjugates synthesized b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/385A61K47/48A61P11/00A61P31/04
Inventor 李建平
Owner KANVAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com